NCT05839951View on ClinicalTrials.gov

An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions

Active, not recruitingOBSERVATIONAL
Enrollment

818

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
DRUG

Regorafenib (BAY73-4506, Stivarga®)

Oral multitargeted kinase inhibitor

DRUG

TAS-102 (trifluridine and tipiracil, Lonsurf®)

Oral cytotoxic chemotherapy

DRUG

Bevacizumab

VEGFR inhibitor

Trial Locations (1)

07981

Many locations, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05839951 - An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions | Biotech Hunter | Biotech Hunter